Table 2. Kaplan-Meier Estimates of Clinical Outcomes at 5 Years for Patients With a Recurrence Score of 26 to 100 Assigned to Chemotherapy Stratified by Adjuvant Chemotherapy Regimen in the Intention-to-Treat Population^a.

Variable	Mean (SE) [95% CI]
	All Patients	Taxane and Cyclophosphamide	Anthracycline Without Taxane	Anthracycline and Taxane	CMF	Other	No Chemotherapy
No.	1389	589	334	244	52	81	89
Invasive disease-free survival	87.6 (1.0) [85.5-89.4]	88.1 (1.5) [84.8-90.8]	87.4 (2.0) [83-90.8]	88.6 (2.3) [83.2-92.3]	84 (5.6) [69.3-92.1]	91.3 (3.4) [81.5-96]	79.7 (4.9) [67.9-87.5]
Freedom from recurrence of breast cancer at a distant site	93.0 (0.8) [91.4-94.4]	92.7 (1.2) [90-94.7]	92.3 (1.6) [88.5-94.9]	95.1 (1.5) [91-97.3]	88.5 (4.8) [74.6-95.1]	95.5 (2.5) [86.8-98.5]	92.8 (3.1) [83.6-97]
Freedom from recurrence of breast cancer at a distant or local-regional site	91.0 (0.8) [89.1-92.5]	91.0 (1.3) [88-93.2]	90.1 (1.8) [86-93]	93.6 (1.7) [89.1-96.2]	88.7 (4.8) [74.9-95.1]	95.5 (2.5) [86.8-98.5]	84 (4.5) [72.8-90.8]
Overall survival	95.9 (0.6) [94.6-96.9]	95.8 (0.9) [93.6-97.2]	96.7 (1.0) [93.9-98.2]	97.2 (1.1) [93.8-98.7]	90.1 (4.7) [75.8-96.2]	97.2 (2.0) [89.2-99.3]	90.7 (3.7) [80.3-95.7]

Abbreviation: CMF, cyclophosphamide/methotrexate/5-fluorouracil.

^aFive-year Kaplan-Meier estimates (percent), standard error, and 95% confidence intervals shown.